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The Journal of Immunology
Hypercholesterolemia Induces a Mast Cell–CD4+ T Cell
Interaction in Atherosclerosis
Eva Kritikou,* Thomas van der Heijden,* Maarten Swart,* Janine van Duijn,*
Bram Slütter,* Anouk Wezel,† Harm J. Smeets,† Pasquale Maffia,‡,x,{ Johan Kuiper,*
and Ilze Bot*
Mast cells (MCs) are potent innate immune cells that aggravate atherosclerosis through the release of proinflammatory mediators
inside atherosclerotic plaques. Similarly, CD4+ T cells are constituents of the adaptive immune response and accumulate within the
plaques following lipid-specific activation by APCs. Recently it has been proposed that these two cell types can interact in a direct
manner. However, no indication of such an interaction has been investigated in the context of atherosclerosis. In our study, we
aimed to examine whether MCs can act as APCs in atherosclerosis, thereby modulating CD4+ T cell responses. We observed that
MCs increased their MHC class II expression under hyperlipidemic conditions both in vivo and in vitro. Furthermore, we showed
that MCs can present Ags in vivo via MHC class II molecules. Serum from high-fat diet–fed mice also enhanced the expression of
the costimulatory molecule CD86 on cultured MCs, whereas OVA peptide–loaded MCs increased OT-II CD4+ T cell proliferation
in vitro. The aortic CD4+ and TH1 cell content of atherosclerotic mice that lack MCs was reduced as compared with their wild-type
counterparts. Importantly, we identified MCs that express HLA-DR in advanced human atheromata, indicating that these cells
are capable of Ag presentation within human atherosclerotic plaques. Therefore, in this artice, we show that MCs may directly
modulate adaptive immunity by acting as APCs in atherosclerosis. The Journal of Immunology, 2019, 202: 1531–1539.
A
therosclerosis is a chronic, lipid-mediated, autoimmune
disease of the medium and large-sized arteries. The
disease is established through circulation of low-density
lipoproteins (LDL) at excessive levels, a process termed hyper-
cholesterolemia (1). LDL molecules can damage and penetrate the
arterial wall and upon oxidation give rise to lipid-rich, highly
inflamed atherosclerotic plaques (2). Atherosclerosis development
involves both innate and adaptive immune responses (3). Com-
munication between the innate and adaptive immune system is
achieved through professional APCs, such as dendritic cells, that
can specifically activate T lymphocytes with Ags taken up from
the atherosclerotic plaque (4). It has been established that during
progression of atherosclerosis, Ags from oxidized LDL (oxLDL)
can elicit immune responses by activating an array of T cell
subsets (5, 6). This occurs within secondary lymphoid tissues,
such as the spleen and local draining lymph nodes where Ags are
presented through MHC class I or MHC class II (MHC-II) (7).
Subsequently, activated T cells translocate to the atherosclerotic
plaque and influence the disease outcome locally (8). The effect
evoked by different T cell subsets, such as TH1 or TH2 cells, is
mainly attributed to their distinct cytokine profile. For example,
TH1 cells, the most abundant Th cell type in progressing athero-
sclerotic plaques (9), release large amounts of IFN-g, whereas
TH2 cells are found at lower numbers and secrete mainly IL-4,
IL-5, and IL-13 (10). CD4+ TH1 cells and IFN-g have been proven
to be proatherogenic (11, 12), whereas TH2 cell function is more
difficult to define (13, 14). IL-5 shows an atheroprotective action
(15), whereas IL-4 appears to induce atherosclerosis (16). How-
ever, these cytokines cannot be strictly appointed to TH2 cells
alone. Interestingly, blockade of costimulatory molecule OX40L,
which specifically lowered TH2 responses, reduced atherosclerosis
levels (17). Thus, the exact role of TH2 cells in atherosclerosis is
still under debate. It is clear, however, that the diversity of T cell
subsets, in terms of both quality and quantity, can exert inverse
effects on the progression of atherosclerosis. Although effector
T cells have in principle a pre-established fate upon entering the
vessel wall, local costimulation in the plaques (18, 19) may alter
their behavior.
Mast cells (MCs) are tissue-resident innate immune cells that
have long been established to contribute to atherosclerosis pro-
gression (20). Their accumulation within the atherosclerotic tissue
upon plaque development, and their subsequent classical mode of
activation, results in the release of proinflammatory mediators,
such as proteases and cytokines (21, 22). Yet increasing evidence
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suggests that MCs can also adopt an Ag-presenting phenotype that
may influence the immune response inside tissues (23). MCs are
not classical APCs like dendritic cells or macrophages. However,
peritoneal MCs have been found to upregulate MHC-II in the
presence of cytokines IL-4 and IFN-g (24), as well as inside the
lymph nodes of mice injected with LPS (25). Importantly, mouse
bone marrow–derived MCs have been reported to present peptides
of the model Ag OVA to CD4+ T cells (26). Likewise, human
cultured MCs can directly present Ags to CD4+ T cells through the
human MHC-II cell surface receptor, HLA-DR (27, 28). However,
to date, it is still unknown whether MCs can directly influence
the adaptive immune response during atherosclerotic plaque
progression. Therefore, we aimed to study the Ag presentation
capacity of MCs to CD4+ T cells in atherosclerosis. We found that
MCs are capable of presenting Ags through their MHC-II ma-
chinery and modify the CD4+ T effector cell response during
hyperlipidemia and atherosclerosis development.
Materials and Methods
Animals
All animal work was performed in compliance with the guidelines directed
by the European Union Directive 2010/63EU and the Dutch Government.
The experimental work was approved by the Animal Ethics committee of
Leiden University. The animals were originally obtained by the Jackson
Laboratories and subsequently bred in the local animal facility while being
provided with food and water ad libitum. At experimental end point, mice
were s.c. anesthetized with an injection mix of ketamine (100 mg/ml),
Sedazine (25 mg/ml), and atropine (0.5 mg/ml), and their vascular
system was perfused with PBS upon heart puncture in the left ventricle.
Western-type diet time-course experiment
To examine the effect of Western-type diet (WTD) on the Ag presentation
capacity of MCs, we performed a time-course experiment (Supplemental
Fig. 1A). Male LDL receptor (LDLr)2/2 mice (n = 10 per group) with an
average age of 8–10 wk were placed on a WTD (0.25% cholesterol, 15%
cocoa butter; Special Diet Services, Essex, U.K.) for either 4 or 8 wk or
kept on a chow diet until the experimental end point. Mouse peritoneal
cells were collected by peritoneal lavage, using 10 ml PBS, to study the
MC peritoneal population according to their characteristic expression of
markers FcεRIa and CD117. Notably, the peritoneal MC population was
also examined for the expression of the myeloid cell marker CD11c, to
ensure that the observed population were not MHC-II+ dendritic cells or
macrophage foam cells, as these cells have been previously reported to
express inducible Fcε receptors in atopic dermatitis, allergy, and inside
atherosclerotic plaques (29, 30). The para-aortic lymph nodes of these
mice were isolated at the experimental end point and fixed in formalin for
24 h. Subsequently, all lymph nodes were embedded in OCT medium
(Sakura), and 6-mm cryosections were collected. MC detection was
performed using a Naphthol AS-D Chloroacetate Esterase kit (Sigma-
Aldrich). The T cell population in the para-aortic lymph nodes was de-
tected through Ab staining against CD3 at a 1:150 concentration (clone
SP7; Thermo Fisher Scientific). Determination of all MC and CD3+ T cell
numbers was performed by blinded and independent manual quantification
of two collected sections per mouse. Representative pictures were obtained
using a Leica DMRE microscope (Leica Systems).
Ea presentation experiment
To study the ability of MCs to present Ags through their MHC-II molecule,
we made use of the Ea-GFP/Y-Ae presentation system whereupon an
Ea-GFP peptide, after internalization and degradation, can be presented by
the MHC-II molecules on the surface of APCs and is detected by specif-
ically designed Abs against Ea fragments (31). We performed an Ea-GFP
complex presentation experiment (32, 33), as described in Supplemental
Fig. 1B, in which male LDLr2/2 mice (n = 14 per group, average age
13 wk) were placed on a WTD for 4 wk. Twenty-four hours prior to the end
of the experiment, one group was injected i.p. with Ea-GFP (100 mg/mouse),
whereas an additional group was administered sterile PBS as a control.
Peritoneal cells isolated from Ea-treated mice were further stimulated ex
vivo with Ea-GFP (200 mg/ml) for either 3 or 24 h and compared with
peritoneal cells isolated from the PBS-injected mice. The expression levels of
an Y-Ae–streptavidin Ab against Ea were determined by flow cytometry in
comparison with the control-PBS expression.
Bone marrow–derived MC stimulation
To investigate the Ag presentation function of MCs in vitro, bone marrow–
derived MCs were cultured from isolated bone marrow cells in RPMI 1640
medium containing 25 mM HEPES (Lonza) supplemented with 10% FCS,
(13) minimal essential medium nonessential amino acids (Life Technol-
ogies), 60 mM 2-ME (Sigma-Aldrich), 1% mix of penicillin/streptomycin
(Lonza), 1% sodium pyruvate (Sigma-Aldrich), and 2% L-glutamine
(Lonza) for 4 wk with cytokine IL-3 (5 ng/ml; ImmunoTools). MC purity
was assessed by the expression of FcεRIa and CD117 and routinely found
to be above 98%. Mature MCs kept in culture for weeks 4–6 were used for
all experiments. MHC-II–induced MCs were obtained by a mix of cyto-
kines IL-4 (20 ng/ml) and IFN-g (50 ng/ml). Subsequently, to study the
effect of hyperlipidemic serum, MCs were stimulated for 24 h with 10%
serum isolated from either chow-fed or 4 wk WTD–fed LDLr2/2 mice and
all conditions were renewed for an additional period of 24 h. MCs were
additionally stimulated with 40% peritoneal fluid, which was obtained by
peritoneal lavage with 10 ml PBS and after centrifugation at 1.600 RPM
for 5 min. After a period of 24 h, all conditions were renewed accordingly.
Cytokine IFN-g and IL-4 secretion was measured by ELISA (BD Biosciences)
according to the manufacturer’s protocol.
MC–OT-II CD4+ T cell coculture
To study the direct presentation of Ags by MCs to CD4+ T cells in vitro we
made use of the OVA presentation system. In a coculture experiment, MCs
were repeatedly treated with 10% chow/WTD serum, as described above,
in the presence of a chicken OVA 323–339 peptide (10 mg/ml) that
can directly bind the MHC-II (I-Ab) surface molecules and is directly
presented to the TCR without requiring internalization. CD4+ T cells were
isolated from genetically modified OT-II mice (34) using a magnetic bead
isolation kit (Miltenyi Biotec) and activated with anti-CD3 (1 mg/ml) and
anti-CD28 (0.5 mg/ml) for 24 h. Subsequently, after washing off the stim-
ulants, MCs and T cells were placed together in a coculture system. Cells
were seeded in quintuplicate per condition at a 1:1 ratio for 72 h. At the end
of the experiment, all samples were prepared for flow cytometry. For the
proliferation assay, radioactive [3H]thymidine (0.5 mCi/well; PerkinElmer)
was added to the samples after 48 h and the incorporation rate was measured
15 h later using a liquid scintillation analyzer (Tri-Carb 2900R).
MC deficiency experiment
To investigate the effect of MCs on the T cell population in atherosclerosis,
male MC-deficient apoE2/2/KitW-sh/W-shmice as well as control apoE2/2mice
(Supplemental Fig. 1C) (n = 16 group, average age 16 wk), were fed a
WTD for 6 wk. The intraplaque cell content was obtained through en-
zymatic digestion of the aortic tissue with a mix of collagenase I (450 U/ml;
Sigma-Aldrich), XI (250 U/ml Sigma-Aldrich), DNase (120 U/ml; Sigma-
Aldrich), and hyaluronidase (120 U/ml; Sigma-Aldrich), and samples were
further processed using flow cytometry.
Human specimens
To explore the ability of human intraplaque MCs to present Ags, 20 anon-
ymous atherosclerotic plaques were collected postoperatively from carotid or
femoral artery endarterectomy surgeries performed between July 2016 and
December 2016 at the Haaglanden Medical Center, Westeinde, The Hague,
The Netherlands. The handling of all human samples was performed in ac-
cordance with the Code for Proper Secondary Use of Human Tissue. All
atherosclerotic samples were processed in single-cell suspensions, as de-
scribed previously (35). In short, cell suspensions from human atherosclerotic
plaques were obtained upon digestion with collagenase IV (Life Technolo-
gies) and DNase (Sigma-Aldrich) for 2 h at 37˚C prior to single-cell sepa-
ration through a 70-mm cell strainer. All human WBC populations were
characterized by flow cytometry, based on the expression of the panleukocyte
marker CD45. The MCs were identified by the FcεRIa and CD117 Abs.
Flow cytometry
All cell populations are depicted as the percentage of viable cells, deter-
mined according to a fixable viability dye solution (eBioscience). Gating
strategies and controls are shown in Supplemental Fig. 2. Cells were stained
with Abs against extracellular proteins or fixated and permeabilized using
a transcription factor kit (eBioscience) for intracellular stainings (Table I).
Flow cytometry measurements were performed on a FACS Canto II and
data were analyzed using FlowJo software.
Statistics
All data are presented as mean 6 SEM. Values within groups were
tested for normal distribution and corrected with a Bonferroni posttest for



















multiple comparisons. In the event of one-variable analysis between two
groups, a two-tailed Student t test was used, whereas among more than two
groups, a one-way ANOVA was performed. For the analysis of two vari-
ables between groups, a two-way ANOVA test was used. Non-Gaussian
distributed data were analyzed with a Mann–Whitney U test. Pearson
correlation was used to estimate the association between two variables in
human MCs. The p (a) value for all tests was set to 0.05, with differences
lower than this considered significant (p , 0.05).
Results
WTD increases the MHC-II expression on peritoneal MCs
To determine the Ag presentation properties of MCs in the course of
high lipid diet, we fed LDLr2/2 mice a WTD for a period of 4 or
8 wk, during which time these mice developed high cholesterol
levels in their blood because of ineffective LDL clearance (36), and
compared the peritoneal MC population with LDLr2/2 mice fed a
chow diet. Exposure to WTD for a prolonged time significantly
increased the proportion of MCs in the peritoneum (Fig. 1A; chow:
0.39 6 0.1% versus WTD 4 wk: 1.97 6 0.4%, p = 0.014; chow
versus WTD 8 wk: 2.02 6 0.3%, p = 0.011). Interestingly, we
observed that during 4 wk of WTD, the peritoneal MC population
showed enhanced expression of the Ag-presenting protein MHC-II
(Fig. 1B; chowMCs: 30.386 1.7% versus WTD 4 wkMCs: 52.486
5.9%, p = 0.014). Furthermore, the para-aortic lymph nodes of these
mice showed a mild increase in the number of MCs after 4 wk of
WTD, as compared with the chow-fed mice (Supplemental Fig. 3A,
3B). However, no difference was observed between the groups in
the number of T cells in the lymph nodes (Supplemental Fig. 3C).
MHC-II molecules on peritoneal MCs can present Ags in vivo
We next sought to examine whether the MHC-II molecules
expressed by peritoneal MCs are functional and capable of
presenting Ags in vivo. To that end, we used the Ea-GFP/Y-Ae
presentation system, which is designed to detect MHC-II–restricted Ag
presentation (37). Specifically, the Ea-GFP/Y-Ae system can identify
Ag presentation in vivo through the ability of Y-Ae Ab to recognize
the Ea peptide in the context of MHC-II binding (I-Ab) (31, 32). We
therefore injected the Ea peptide or PBS control in the peritoneum of
WTD-fed LDLr2/2 mice. After 24 h we observed that the MHC-II
expression was higher in the Ea-injected MCs as compared with
control (Fig. 2A; PBS: 10.99 6 2.13% Ea: 21.176 3.8% p = 0.037).
Importantly, Ea peptide fragments were detected on the MC surface of
the Ea-injected group, using Y-Ae (Fig. 2B; PBS: 2.306 0.2% versus
Ea: 7.35 6 1.7%, p = 0.0160). We further examined the capacity of
peritoneal MCs to present the Ea peptide ex vivo. Three hours after
peptide addition, the Ea-GFP+ signal was detected in peritoneal MCs,
indicating that the peptide is internalized but not yet processed in the
lysosomal compartment (Fig. 2C; PBS: 0 versus Ea [3 h]: 7.25 6
1.6%, p = 0.0003; versus Ea [24 h]: 5.25 6 1.8% p = 0.004). After
24 h, Ea peptide fragments were detected on the peritoneal MC
surface, indicating that during this period the Ea peptide was fully
processed by the lysosomes and its fragments were presented on the
MC surface through the MHC-II molecule (Fig. 2D; PBS: 2.52 6
0.9% versus Ea [24 h]: 26.02 6 9.1%, p = 0.0033). As a control
reference for the Ea-GFP/Y-Ae presentation system, we examined the
Ea peptide presentation efficiency in dendritic cells from the perito-
neal cavity treated with Ea-GFP ex vivo (Supplemental Fig. 4A, 4B).
WTD serum enhances the presentation capacity of bone
marrow–derived MCs in vitro
Because WTD-induced hypercholesterolemia seemed to enhance
the presentation machinery of MCs, we aimed to further investigate
the direct effect of hyperlipidemic serum on theMHC-II expression
FIGURE 1. Peritoneal MCs of LDLr2/2 mice increase in amount and MHC-II expression after 4 wk of WTD. Representative flow cytometry plots are
shown, with the MC population defined by the expression of receptors FcεRIa and CD117. The MC percentage in the peritoneal cavity of LDLr2/2 mice
increased after 4 and 8 wk of WTD (A). Characteristic dot plots of the MHC-II expression on the MC population show the peritoneal MCs that express
protein MHC-II (B). All values (n = 5 per group) are depicted as mean 6 SEM. *p , 0.05.



















of MCs. We therefore used bone marrow–derived MCs to examine
the effects of atherogenic serum from LDLr2/2 mice fed a WTD for
4 wk compared with serum from chow-fed LDLr2/2 mice. Unlike
peritoneal MCs (38), bone marrow–derived MCs are not able to
constitutively express MHC-II (39) unless induced with specific
stimulation factors (24, 25). For that reason, we induced MHC-II
expression on the MCs using IL-4 and IFN-g (Supplemental Fig.
4C). This is not necessary in vivo, potentially because the inflam-
matory status of hyperlipidemic serum already contains these cyto-
kines (40). Indeed, we observed that upon repeated treatment of MCs
with WTD (4 wk) serum for 48 h, MCs increased their MHC-II
expression levels by 2-fold as compared with chow serum (Fig.
3A; chow MC: 3.12 6 0.3% versus WTD MC: 10.25 6 0.1%;
p , 0.0001). Furthermore, the costimulatory protein CD86, which is
required for efficient T cell activation (41), was also increased onWTD
MCs, as compared with chow MCs (Fig. 3B; chow MC: 1.73 6 0.1%
versus WTD MC: 2.53 6 0.1%, p = 0.0012). Interestingly, when
MCs were treated with fluid collected from the peritoneal cavity of
LDLr2/2mice fed either chow or WTD (4 wk), they showed a marked
increase in their MHC-II expression (Supplemental Fig. 4D). We
measured the IL-4 and IFN-g levels in the peritoneal cell fluid and
observed that both cytokines are present (Supplemental Fig. 4E, 4F),
indicating that the peritoneal cavity locally possesses the necessary
signals for MHC-II induction on the MCs in vivo.
OVA-specific CD4+ T cell proliferation is enhanced upon
coculture with WTD-treated MCs
Next, we aimed to detect the direct effect of MC-mediated Ag
presentation onto CD4+ T cells. We isolated CD4+ T cells from
genetically modified OT-II mice that specifically recognize
chicken OVA peptide in the context of MHC-II (34), and after 24 h
of preactivation with anti-CD3/CD28 we placed them in a co-
culture with MCs preloaded with an OVA peptide in the tempo-
rary presence of 10% chow or WTD diet serum. OT-II CD4+
T cells cocultured with both chow and WTD MCs increased
their proliferation rate upon OVA peptide presentation, based on the
incorporation rate of [3H]thymidine. However, this increase was
enhanced by 2-fold when OT-II CD4+ T cells were cocultured with
OVA peptide–loaded WTD MCs, as compared with coculture with
OVA peptide–loaded chow MCs (Fig. 4A; chow MCs: 90336 2558
dpm versus WTD MCs: 25331 6 2889 dpm, p , 0.0001). The
WTD effect of OVA peptide–loaded MCs on the proliferation rate
of CD4+ T cells was further confirmed by flow cytometry upon
detection of the intracellular proliferation marker Ki-67 on the
CD4+ T cell population (Fig. 4B; chow MCs: 17.766 0.09% versus
WTD MCs: 25.56 6 1.7%, p = 0.004).
Aortic CD4 + T cells show reduced proliferation in
MC-deficient mice
To verify whether MCs affect the CD4+ T cell population in the
atherosclerotic plaque, we placed MC-deficient apoE2/2/KitW-sh/W-sh
FIGURE 2. The MHC-II protein on the perito-
neal MC surface is able to present epitopes of the
Ea peptide upon WTD. LDLr2/2 mice, fed a WTD
for 4 wk, increased their MHC-II expression levels
24 h after i.p. injection of Ea-GFP, as compared
with PBS-injected mice (A). The Ea peptide frag-
ments were detected in vivo on the surface of
peritoneal MCs, 24 h after Ea administration (B).
Peritoneal cells isolated from the PBS and Ea-
administered mice were further treated ex vivo with
Ea-GFP+ protein. Ea-GFP+ uptake by peritoneal
MCs was detected at 3 and 24 h after addition (C).
E peptide fragments (Y-Ae+) were observed 24 h
later, on the peritoneal MC surface (D). All values
(n = 10 per group) are depicted as mean 6 SEM.
*p , 0.05, **p , 0.01, ***p , 0.001.
FIGURE 3. Inducible bone marrow–derived MCs repeatedly treated with
WTD serum possess the signals required for Ag presentation. The expression
of MHC-II on the surface of bone marrow MCs increased upon repeated (48 h)
in vitro treatment with 10% serum isolated from LDLr2/2mice that were fed a
WTD for 4 wk, as compared with chow serum (A). Costimulatory molecule
CD86 was enhanced on the surface of MCs after treatment with 10% WTD
(4 wk) serum from LDLr2/2 mice in comparison with chow serum (B). All
values are shown as mean 6 SEM. **p , 0.01, ****p , 0.0001.



















mice, which show significantly elevated (V)LDL cholesterol levels
in their blood (36), on a WTD and compared the CD4+ T cell
content in the aortic arch with that from WTD-fed control apoE2/2
mice. Using flow cytometry, we observed a reduction in the
percentage of CD4+ T cells in the aorta of atherosclerotic MC-
deficient mice, as compared with control (Fig. 5A; apoE2/2:
4.72 6 0.8% versus apoE2/2/KitW-sh/W-sh: 2.37 6 0.7, p = 0.028).
Moreover, the proportion of proliferating aortic CD4+ T cells, as
defined by the expression of Ki-67, was significantly reduced in
atherosclerotic-deficient mice as opposed to control (Fig. 5B;
apoE2/2: 30.91 6 5.2% versus apoE2/2/KitW-sh/W-sh: 13.07 6
1.2, p = 0.013). A similar trend was observed when examining
the absolute number of proliferating CD4+ T cells (Fig. 5C;
apoE2/2: 1725 6 567 cells versus apoE2/2/KitW-sh/W-sh: 389 6
59 cells, p = 0.056). Interestingly, a significant decline in the
number of TH1 cells was also detected in the aortas of MC-
deficient apoE2/2 mice as compared with control apoE2/2
mice (Fig. 5D; apoE2/2: 148 6 25 cells versus apoE2/2/KitW-sh/W-sh:
45 6 16 cells, p = 0.0042).
Human intraplaque MCs express HLA-DR
Finally, to establish whether our murine data are relevant to the
human disease setting, we analyzed the MC content of 20 end-
arterectomy plaques collected from carotid or femoral arteries.
Of note, we used flow cytometry for the detection of human
intraplaqueMCs. Specifically, in femoral as well as carotid arteries,
MCs were detected by the expression of receptors FcεRIa and
CD117 (Fig. 6A). Focusing on the Ag presentation capacity of
MCs within atherosclerotic plaques, we stained the MCs for the
expression of HLA-DR. We observed that MCs inside human
atherosclerotic plaques express HLA-DR in both femoral and
carotid arteries (Fig. 6B). Interestingly, the HLA-DR–expressing
cells showed a negative association with the activated MC
population, as detected by marker CD63 (42), which comprises
the majority of MCs within the atherosclerotic plaque (Fig. 6C,
Table I).
Discussion
In this project, we examined whether MCs are able to contribute to
MHC-II–restricted activation of CD4+ T effector cells in athero-
sclerosis. We observed that hyperlipidemic inflammatory condi-
tions induced the expression of MHC-II by peritoneal MCs and,
furthermore, that MCs were capable of presenting Ags in vivo and
in vitro. Within the atherosclerotic plaques, MCs appear to aug-
ment the local TH1 response because their absence resulted in
reduced CD4+ T cell proliferation and a lower TH1 aortic cell
content. Importantly, we showed in this study that MCs express
HLA-DR in human atherosclerotic plaques and may therefore be
capable of Ag presentation in human subjects.
The capacity of MCs to modulate effector T cell responses when
influenced by inflammatory signals in their microenvironment is a
process that has recently gained attention in the field (43, 44). Here
we observed that mouse MCs increase their MHC-II levels,
both in vivo and in vitro, in a WTD-specific manner. In accor-
dance, we detected high levels of IFN-g in the peritoneal fluid
of hyperlipidemic mice. Furthermore, the absence of MCs sig-
nificantly reduced the number of TH1 cells, the main producers
of IFN-g inside the atherosclerotic plaques (45). In the past, a
study reported that rat MCs incubated with IFN-g show increased
MHC-II expression, arguing that aside from their classical role
as degranulating effector cells, MCs may also be capable of
presenting Ags and thus affecting T cell function (46). Addi-
tionally, peritoneal MCs in the presence of IFN-g and IL-4 (24)
have been shown to increase their MHC-II expression levels. The
regulation of MHC-II by IFN-g has previously been established in
macrophage cell lines (47) but also in human MCs (48). Inter-
estingly, human plaque tissue contains high amounts of IFN-g
(49), and patients suffering from coronary heart disease show
increased levels of IFN-g in their serum (50). This may explain
why MCs increase their MHC-II expression specifically within an
atherosclerotic environment.
In addition, we noticed that MCs can also express costimulatory
signals, in the form of CD86, which are indispensable for Ag
presentation. Specifically, WTD conditions increased CD86
expression. However, other costimulatory molecules could also
participate in the described interaction with CD4+ T cells. The
presence of multiple costimulatory molecules on the MC surface,
such as OX40L and CD80, was suggested to mediate direct
communication with CD4+ T cells (25, 51).
Importantly, in this study we establish that the MHC-II protein
on the surface of MCs is a fully functional molecule that can bind
and present Ags processed by the lysosomal machinery of the cell
and successfully transport them to the cell surface where they can
be introduced to CD4+ T cells. Nonetheless, MCs are poor acti-
vators of naive T cells (25). In atherosclerosis, however, the ma-
jority of T cells infiltrating the plaque or the peritoneal cavity are
previously activated and thus can be directly influenced by MCs.
In this rationale, we aimed to study the direct interaction of MCs
with preactivated CD4+ T cells. Additionally, although the Ea and
OVA peptides are model Ags that serve in exploring the presen-
tation capacity of a cell, the WTD-specific induction of MHC-II
raises the possibility of lipid-specific Ag presentation by MCs. It
FIGURE 4. Bone marrow MCs, treated with WTD serum and loaded
with OVA peptide, enhance the proliferation rate of preactivated OT-II
CD4+ T cells. OT-II CD4+ T cells increased their proliferation upon pre-
sentation of OVA peptide (OVAp) by MCs treated with WTD, as compared
with chow-treated MCs, based on radioactive thymidine incorporation
and expression of proliferation marker Ki-67+ (A and B). All values (n = 5
per group) are shown as mean 6 SEM. **p , 0.01, ***p , 0.001,
****p , 0.0001.



















is worth mentioning that oxLDL is known to activate both mac-
rophages and MCs (52). Also, oxLDL immune complexes can
induce proatherogenic cytokine secretion by the MCs (53). In fact,
the way by which MCs are activated within the atherosclerotic
tissue has not yet been fully deciphered. Although the classical
FcεR pathway is a plausible explanation, oxLDL can activate
FIGURE 5. MC-deficient apoE2/2/KitW-sh/W-sh
mice show a reduction in the proliferation of CD4+
TH1 cells in the aortic arch. The CD4
+ T cell
content was significantly decreased in the aortas of
WTD-fed apoE2/2 mice upon the absence of MCs
(A). The percentage and absolute numbers of pro-
liferating Ki-67+/CD4+ T cells were reduced in the
aortic arch of apoE2/2/KitW-sh/W-sh mice fed a
WTD for 6 wk as compared with apoE2/2 mice
(B and C). The number of TH1 cells in the aorta of
MC-deficient apoE2/2 mice was decreased, as
measured by the expression of transcription factor
T-bet on the aortic CD4+ T cell population (D).
All values (n = 8 per group) are depicted as
mean 6 SEM. *p , 0.05, **p , 0.01.
FIGURE 6. Human MCs from carotid and fem-
oral atherosclerotic plaques express HLA-DR. The
MC population in the plaques of human subjects,
obtained from endarterectomy surgery, is detected
based on the high expression of FcεRΙa and
CD117. Representative flow cytometry plots of
human MCs are shown, gated according to the
expression of receptors FcεRIa and CD117 (A).
Human intraplaque MCs expressed HLA-DR in the
femoral artery and carotid artery samples (B). The
HLA-DRhi MCs showed a negative correlation with
the activated CD63+ MC population in the athero-
sclerotic arteries (C).



















human MCs in a TLR4-dependent mode (54). This is important,
considering that TLR4 signaling on APCs enhances Ag pre-
sentation (55). Interestingly, MCs have been previously reported
to influence both the innate (56) and the adaptive immune re-
sponse through TLR signaling (57). It would therefore be in-
triguing to see if an oxLDL/TLR-mediated pathway is shaping
the Ag specificity of presenting MCs. Overall, it is interesting to
investigate the means through which MCs may take up Ags
from their surrounding atherosclerotic environment as, to our
knowledge, there are no reports of MCs advancing into a foam
cell state. Nonetheless, MCs have been reported in the past to
affect intraplaque macrophages (58), whereas they were found
to also interact with dendritic cells and actively exchange in-
tracellular material and Ags (59) or even MHC-II molecules
(60). In such a way, MCs can shape T cell responses in as much
a direct as an indirect manner.
To gain a translational impression on the MC Ag presentation
capacity, we applied flow cytometry to study human MCs within
atherosclerotic plaques. It is known that human and mouse MCs
share a multitude of characteristics, and although humanMCs show
a more complex secretome (61), their origin and tissue maturation
processes are similar (62, 63). Furthermore, atherosclerosis studies
on both murine and human MCs (64) highlight akin functions that
may permit translation from rodents to humans. One example is
the association of MCs with intraplaque hemorrhage reported in
both mice (65) and humans (66). In our study, we observed that
intraplaque MCs show high levels of CD63, an activation marker
linked to the FcεR-mediated degranulation (42). However, their
CD63 expression was negatively correlated to the HLA-DR MC-
expressing population. Although this does not indicate a causal
relationship, it suggests that MCs engaging in the presentation of
Ags may not be activated at the same time. In the future, it would
be of interest to explore this relationship between MC presentation
and degranulation and to further address the differences in MC
functionality between normal chow diet and high-fat diet condi-
tions. Furthermore, HLA-DR expression by human MCs has also
been previously reported in human tonsils and the authors suggest
that it mediates Ag presentation by MCs to CD4+ T cells (27).
Importantly, a very recent study investigating the presentation
capacity of human skin MCs provides additional evidence that
these cells can also express HLA-DM in an IFN-g–specific
manner and directly present Ags to CD4+ T cells, further shaping
thus the TH1 response (67).
Finally, it is worth mentioning that examination of the Ag
presentation capacity of MCs shows slight discrepancies in
different studies with regard to their costimulatory molecule
expression and influence on CD4+ T cell responses (43). This
diversity may originate from the differential in vitro generation
of MCs from bone marrow progenitors but also from the dif-
ferent MC-deficient animal models. It is important to remember
that MCs are found only within tissues, whereupon they un-
dergo the last step of differentiation, influenced by local
stimuli.
In conclusion, this study shows that MCs are capable of
presenting Ags in a hypercholesterolemic environment and
this pathway can potently modulate CD4+ T effector cells toward
a proatherogenic TH1 phenotype within atherosclerotic plaques.
The Ag-presentation capacity of MCs in both mice and hu-
mans indicates that these cells can directly shape the adaptive
immune responses, apart from exacerbating the innate in-
flammatory pathways. Further research on how to modulate
this interaction may lead to novel ways to limit atherosclerosis
development.
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1. Zárate, A., L. Manuel-Apolinar, R. Saucedo, M. Hernández-Valencia, and
L. Basurto. 2016. Hypercholesterolemia as a risk factor for cardiovascular
disease: current controversial therapeutic management. Arch. Med. Res. 47:
491–495.
2. Holvoet, P., G. Theilmeier, B. Shivalkar, W. Flameng, and D. Collen. 1998. LDL
hypercholesterolemia is associated with accumulation of oxidized LDL, ath-
erosclerotic plaque growth, and compensatory vessel enlargement in coronary
arteries of miniature pigs. Arterioscler. Thromb. Vasc. Biol. 18: 415–422.
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